Saikosaponin D improves nonalcoholic fatty liver disease via gut microbiota-bile acid metabolism pathway
文献类型:期刊论文
作者 | Li, Lan1; Yang, Shengye1,2; Liang, Xinyu3; Liu, Yameng4; Xu, Hualing3; Guo, Xiaozhen4; Xie, Cen3,4; Xu, Xiaojun1,2 |
刊名 | Food Science and Human Wellness |
出版日期 | 2023-11-03 |
关键词 | Gut Microbiota Non-alcoholic Fatty Liver Disease Ssd Bile Acids Farnesoid x Receptor |
DOI | 10.26599/FSHW.2022.9250218 |
英文摘要 | Non-alcoholic fatty liver disease (NAFLD) is the main cause of chronic liver disease worldwide. Bupleurum is widely used in the treatment of non-alcoholic fatty liver, and saikosaponin D (SSD) is one of the main active components of Bupleurum. The purpose of this study was to investigate the efficacy of SSD in the treatment of NAFLD and to explore the mechanism of SSD in the improvement of non-alcoholic fatty liver disease based on “gut-liver axis”. Our results showed that SSD dose-dependently alleviated high fat diet-induced weight gain in mice, improved insulin sensitivity, and also reduced liver lipid accumulation and injury-related biomarkers aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Further exploration found that SSD inhibited the mRNA expression levels of farnesoid X receptor (Fxr), small heterodimer partner (Shp), recombinant fibroblast growth factor 15 (Fgf15) and apical sodium dependent bile acid transporter (Asbt) in the intestine, suggesting that SSD improved liver lipid metabolism by inhibiting intestinal FXR signaling. SSD can significantly reduce the gut microbiota associated with bile salt hydrolase (BSH) expression, such as Clostridium. Decreased BSH expression reduced the ratio of unconjugated to conjugated bile acids (BAs), thereby inhibiting the intestinal FXR. These data demonstrated that SSD ameliorated NAFLD potentially through the gut microbiota-bile acid-intestinal FXR pathway and suggested that SSD is a promising therapeutic agent for the treatment of NAFLD. |
语种 | 英语 |
源URL | [http://119.78.100.183/handle/2S10ELR8/309611] |
专题 | 新药研究国家重点实验室 |
通讯作者 | Guo, Xiaozhen; Xie, Cen; Xu, Xiaojun |
作者单位 | 1.State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210029, Jiangsu, China. 2.Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China 3.School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210029, China 4.State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China |
推荐引用方式 GB/T 7714 | Li, Lan,Yang, Shengye,Liang, Xinyu,et al. Saikosaponin D improves nonalcoholic fatty liver disease via gut microbiota-bile acid metabolism pathway[J]. Food Science and Human Wellness,2023. |
APA | Li, Lan.,Yang, Shengye.,Liang, Xinyu.,Liu, Yameng.,Xu, Hualing.,...&Xu, Xiaojun.(2023).Saikosaponin D improves nonalcoholic fatty liver disease via gut microbiota-bile acid metabolism pathway.Food Science and Human Wellness. |
MLA | Li, Lan,et al."Saikosaponin D improves nonalcoholic fatty liver disease via gut microbiota-bile acid metabolism pathway".Food Science and Human Wellness (2023). |
入库方式: OAI收割
来源:上海药物研究所
其他版本
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。